Some individual trials and reports have similarly noted improved mood or reduced depressive symptoms in diabetic patients treated with GLP-1 RAs, potentially as a result of better overall health and possible direct neurochemical effects
User 22 in our observational data highlighted this uncertainty when questioning if he really wanted to continue dosing twice daily in light of the 30-minute half-life
Conclusion: Combined administration of trevogrumab and garetosmab led to
Yang WS, Kim KJ, Gaschler MM, Patel M, Shchepinov MS, Stockwell BR
doi: 10.1523/JNEUROSCI.2105-10.2010, 140 SticeE.YokumS.BohonC.MartiN.SmolenA
However, most of these effects tend to diminish over time as the body adjusts